Page 96 - e-CPG-SLE-8_5_24

Management of Systemic Lupus Erythematosus

ACKNOWLEDGEMENT

The CPG DG members would like to express their gratitude and
appreciation to the following for their contributions:
• Panel of external reviewers who reviewed the draft technically
• Technical Advisory Committee of CPG for their valuable input and
feedback
• HTA and CPG Council for approval of the CPG
• Mr. Latif Abqari Nazeri and Ms. Rosazaddilah Azaddin for the
retrieval of evidence
• All those who have contributed directly or indirectly to the
development of the CPG

DISCLOSURE STATEMENT

The panel members of both DG and RC had completed disclosure forms.
None hold shares in pharmaceutical firms or act as consultants to such
firms. Details are available upon request from the CPG Secretariat.

SOURCE OF FUNDING

The development of the CPG on Management of Systemic Lupus
Erythematosus was supported mainly by the MoH Malaysia and partly
by the Malaysian Society of Rheumatology.

79